Active, Not Recruiting
A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer - CA209-650
Aktualizováno: 5 leden, 2024 | ClinicalTrials.gov
Fáze
Pohlaví
Věková skupina
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Metastatic, castrate resistant prostate cancer (M1 by National Comprehensive Cancer Network (NCCN) criteria) - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Ongoing androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone (GnRH) analogue or a surgical/medical castration with testosterone level of ≤1.73nmol/L (50ng/dL) - Patients with skeletal system symptoms who are already on medications to strengthen bones are allowed if they were started ˃28 days before study treatment - Bone-directed radiotherapy to pelvic region for ease of pain from painful bone metastases is allowed up to 14 days before Exclusion Criteria: - Cancer that has spread to the liver or brain - Active, known, or suspected autoimmune disease or infection - Prior treatment with any drug that targets T cell co-stimulation pathways(such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply
Důrazně doporučujeme kontaktovat BMS a oznámit vedlejší účinky / nežádoucí příhody
Zde jsou definovány vedlejší účinky / nežádoucí příhody a další příhody, které by měly být hlášeny
Nahlásit vedlejší účinky / nežádoucí příhody nebo stížnosti na kvalitu produktu: lékařské informace
